Tvardi Therapeutics (NASDAQ:TVRD) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a hold rating in a research report released on Sunday.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Performance

Shares of Tvardi Therapeutics stock opened at $3.93 on Friday. The company has a market capitalization of $36.87 million, a PE ratio of -0.41 and a beta of 0.14. The company has a 50-day simple moving average of $4.08 and a two-hundred day simple moving average of $12.21. Tvardi Therapeutics has a one year low of $3.50 and a one year high of $43.65.

Hedge Funds Weigh In On Tvardi Therapeutics

Hedge funds have recently made changes to their positions in the company. 683 Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics in the second quarter worth about $4,107,000. Slate Path Capital LP acquired a new position in Tvardi Therapeutics in the second quarter valued at approximately $16,427,000. Geode Capital Management LLC lifted its holdings in Tvardi Therapeutics by 6.2% in the fourth quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock valued at $676,000 after acquiring an additional 9,214 shares during the period. Marshall Wace LLP acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $583,000. Finally, Squarepoint Ops LLC increased its holdings in shares of Tvardi Therapeutics by 534.3% during the 4th quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock valued at $223,000 after purchasing an additional 43,619 shares in the last quarter. 44.66% of the stock is owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.